NCT03459469 - Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2018

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2022

Conditions

Desmoid Tumor

Interventions

DRUG

Tegavivint

This is an Investigational drug

Trial Locations (7)

Memorial Sloan Kettering Cancer Center, New York

The Ohio State University Comprehensive Cancer Center, Columbus

Seattle Cancer Care Alliance, Seattle

MD Anderson Cancer Center, Houston

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston

Princess Margaret Cancer Center, Toronto